CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. - Wikidata - wikimedia - TriplyDB

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

http://www.wikidata.org/entity/Q44273424

about

Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Voriconazole pharmacokinetics and pharmacodynamics in children.Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Fungal infections in transplant and oncology patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism Inflammation is associated with voriconazole trough concentrations.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.In vitro study of the variable effects of proton pump inhibitors on voriconazole Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice.Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole Pharmacogenomics of the triazole antifungal agent voriconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.Pharmacokinetic drug interactions involving Ginkgo biloba.Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.PharmGKB summary: voriconazole pathway, pharmacokinetics.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.

P2860

Q27009221-A78059D1-D2B7-4291-9C08-5B44F33830D4 Q33577291-CA99A5A9-2FBB-45F2-A53C-5EB0A74B9139 Q33608028-192C2E9E-1E04-4CE9-8626-904EACDC8229 Q33665780-FD78BE1C-AB37-4997-8F65-52A51539EFF4 Q33684379-B0E51512-DEA0-4E82-B370-995B5E31B521 Q33849298-CBF1B438-4C3D-46C2-8924-9D9AACAC6C07 Q33896940-C123F112-991C-47B1-84E5-44C7F11A4DFC Q34138276-933A2728-281D-4BDD-B9B0-C991840B3269 Q34213621-364601A8-F8FB-47E0-9A71-40FE83806745 Q34597394-EB73EE83-5A42-461C-A40A-E1E9B2000290 Q35026481-B8EA72F9-43A6-4759-9948-01EFF7E9C30D Q35086478-D6158499-0AE2-4D33-84E7-C3A1EB16C3DA Q35114591-DA02145A-A3ED-423E-9D69-0BF571AFF654 Q35169112-D0DDC618-3381-43CB-89A4-59B7F4FBCA3D Q35364006-2AEE4868-FF60-4BCF-90FF-86707B6AA9F8 Q35617669-FD077FC8-C671-4D72-B332-D4D2F5C5A307 Q35936943-66C5303C-7504-4A21-AB17-B66440BE9EB0 Q35960842-87BF26A4-FE7B-4BA5-8E3D-0B49A2C5E800 Q36172497-AD3218E7-AA42-44DF-8620-7BE3B93BED80 Q36608562-291570AF-1CD6-4D94-9A78-D0E0178188B3 Q36667044-1E332B77-7BBB-48C4-90F7-79CCDFDC1B97 Q36673940-22E150BA-4CF3-464A-8A01-E34C3789D5BE Q36887922-4C431F32-2284-47A0-8753-993D9B8A03CA Q36969849-45EA2688-189E-4A8E-AC5A-1EAF6CA264DE Q37102131-6A1F4901-6CC1-43C8-A632-CF705B7382F7 Q37471073-A85FAF1B-5A16-4B65-9E02-D6D98881CF5E Q37892536-D140DFDA-E6C0-4CD4-9824-61D620B2A7C5 Q37904672-6D2832A2-7C12-458C-91F1-95CFA849FEB0 Q37945308-FFCB6B8B-4491-4C3E-ADB6-E735F175B2A5 Q37964574-3F500985-DB57-47B2-9A85-31B6258A8FD0 Q38073201-274F10F5-418C-4751-9C9D-75F0ABF51B33 Q38122439-7E9749D0-9A14-4DF8-BDDA-96F1AF88945B Q38205729-C5AF9805-7FAD-4FA4-8D94-9C9519C5D51D Q38284468-9E2736A6-2CB3-41A0-BA4D-11C9558A2183 Q38526795-609A0C3B-9960-4FDF-8BA7-6355EDB4E0AC Q38661462-9F0C4D49-BBC2-4A0E-AF8F-8F035DC88E9F Q38775809-65356A01-0E97-41FC-893B-3303877D3F17 Q38889189-9F54C4C5-40EA-421E-B380-86A7AA0AFC4A Q38918175-D0DEE306-9F00-4CB0-A8B3-66ED678072AF Q39196770-61524956-D4AB-49D9-86C0-2CA83C82F39B

P2860

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

http://www.wikidata.org/entity/Q44273424

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@en

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@nl

type

label

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@en

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@nl

prefLabel

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@en

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@nl

P1433

Q44273424-B0AA607D-D80E-4C04-A552-4CC4F963E32E

P1476

Q44273424-86DE790C-F500-45A4-93A3-EC6A7C4BC57E

P2093

Q44273424-136B28A7-E818-4FBE-B143-7714AA30FBC2

Q44273424-3AC29F5E-8E92-4C4A-A81A-6812C318A01D

Q44273424-44394533-F511-4E74-BF9E-741420EC3544

Q44273424-DB7CCCE3-0D82-4A79-9A71-23A99223F4D5

Q44273424-FFF451F0-E21F-40DE-9652-02D89F1B7596

P2860

Q44273424-12DF8010-69C3-4FCD-8F38-834B6EE9DBB7

Q44273424-1347BC26-E18A-4081-B045-221EC99D98EC

Q44273424-13861726-8937-41F9-8F2E-B5BD0FBBE089

Q44273424-25D23EF7-62A8-4494-B819-71BC82EA9424

Q44273424-293F0621-57F5-4112-A11A-4ACBE1D70A3E

Q44273424-386C31A3-6C46-4207-8D68-8525BBC74B5E

Q44273424-3A25D740-839A-48D1-8D87-7F3A47C4EC16

Q44273424-42CF45A1-049D-4010-A729-5D12B080032C

Q44273424-4D67D0EA-621E-4B03-8382-E02A071331BA

Q44273424-50540872-F053-46C4-987A-05196651C07E

P304

Q44273424-AA268A5C-3A48-4565-8D2E-5DBAF9E30046

P31

Q44273424-4796CE01-CE11-4D77-AB0E-03BBD9285A64

P356

Q44273424-EBE2F3E3-86A3-4B8D-A21E-4403BF3B1014

P433

Q44273424-A35A35E8-030C-4F20-B8E1-D0AB5A9CE39C

P478

Q44273424-5AFE8167-9492-4403-AC40-524C05511F0C

P50

Q44273424-7F876915-B6A8-4091-97B7-2C6BCE64FCC6

Q44273424-B773D7D5-1451-4CE6-A618-B468050B5238

Q44273424-EA300944-327C-4266-8296-41FDF419CACE

P577

Q44273424-9FAA4BC2-CA3F-42E8-BFF0-95C77BF0D360

P5875

Q44273424-3BE55B15-95CE-4CA7-91CD-3BA5C31F2603

P698

Q44273424-EB0FE6D2-C055-4F6D-82D2-20043A1082C0

P356

0091270008327537

P1433

The Journal of Clinical Pharmacology

P1476

CYP2C19 genotype is a major fa ...... rmacokinetics of voriconazole.

@en

P2093

Ingeborg Walter-Sack

http://www.w3.org/2001/XMLSchema#string

Jens Rengelshausen

http://www.w3.org/2001/XMLSchema#string

Johanna Weiss

http://www.w3.org/2001/XMLSchema#string

Magdalena Maria Ten Hoevel

http://www.w3.org/2001/XMLSchema#string

Michael Marcus Hoffmann

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

Inhibition of P-glycoprotein by newer antidepressants.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole

CYP3A5 phenotype-genotype correlations in a British population.

ABCB1 pharmacogenetics: progress, pitfalls, and promise.

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Development and validation of a high-performance liquid chromatography assay for voriconazole.

Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values.

Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.

P304

196-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008327537

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Jürgen Burhenne

Walter E Haefeli

P577

2008-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23497302

http://www.w3.org/2001/XMLSchema#string

P698

19033450

http://www.w3.org/2001/XMLSchema#string